치료받지 않은 만성 림프구성 백혈병(CLL)/소림프구성 림프종(SLL) 환자에서 피르토브루티닙(LOXO-305)과 벤다무스틴 플러스 리툭시맙(BR) 비교 연구 (BRUIN-CLL-313)
치료받지 않은 만성 림프구성 백혈병/소림프구성 림프종 환자를 대상으로 Pirtobrutinib(LOXO-305) 대 Bendamustine + Rituximab의 3상 공개, 무작위 연구
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Christchurch, 뉴질랜드, 8011
- Christchurch Hospital
-
Papatoetoe, 뉴질랜드, 2025
- Middlemore Clinical Trials
-
-
Auckland
-
Takapuna, Auckland, 뉴질랜드, 0622
- North Shore Hospital, Haematology Research
-
-
Bay of Plenty
-
Tauranga, Bay of Plenty, 뉴질랜드, 3112
- Tauranga Hospital
-
-
-
-
-
Changhua, 대만, 50544
- Chang Bing Show Chwan Memorial Hospital
-
Taichung, 대만, 40447
- China Medical University Hospital
-
Taipei, 대만, 10002
- National Taiwan University Hospital
-
Taoyuan City, 대만, 333
- Chang Gung Memorial Hospital - Linkou
-
-
-
-
-
Busan, 대한민국, 47392
- Inje Univ Busan Paik Hospital
-
-
Incheon-gwangyeoksi [Incheon]
-
Namdong-gu, Incheon-gwangyeoksi [Incheon], 대한민국, 21565
- Gachon University Gil Medical Center
-
-
Seoul
-
Seocho-Gu, Seoul, 대한민국, 06591
- The Catholic University of Korea-Seoul St. Mary's Hospital
-
-
Seoul, Korea
-
Seoul, Seoul, Korea, 대한민국, 03080
- Seoul National University Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 06351
- Samsung Medical Center
-
-
-
-
-
Saint Petersburg, 러시아 제국, 197022
- Academician I.P. Pavlov First St-Petersburg State Medical University
-
-
-
-
-
Bucharest, 루마니아, 022328
- Institutul Clinic Fundeni - Centrul de Hematologie si Transplant Medular
-
Cluj-Napoca, 루마니아, 400015
- Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca
-
Iași, 루마니아, 700483
- Institutului Regional de Oncologie IASI
-
-
Dolj
-
Craiova, Dolj, 루마니아, 200143
- Spitalul Clinic Municipal Filantropia Craiova
-
-
-
-
California
-
Los Angeles, California, 미국, 90027
- California Research Institute
-
Whittier, California, 미국, 90603
- Innovative Clinical Research Institute
-
-
Florida
-
Coral Springs, Florida, 미국, 33065
- Oncology-Hematology Associates of West Broward
-
-
New Jersey
-
Brick, New Jersey, 미국, 08724
- New Jersey Center for Cancer Research
-
-
New York
-
Westbury, New York, 미국, 11590
- Clinical Research Alliance, Inc.
-
-
-
-
-
Plovdiv, 불가리아, 4000
- UMHAT "Sveti Georgi" EAD
-
Sofia, 불가리아, 1431
- UMHAT 'Sv. Ivan Rilski', EAD
-
Sofia, 불가리아, 1797
- "SHATHD" EAD, Sofia
-
Stara Zagora, 불가리아, 6003
- UMHAT - Prof. Dr. Stoyan Kirkovich" AD
-
-
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre, Rio Grande do Sul, 브라질, 90050-170
- Irmandade da Santa Casa de Misericórdia de Porto Alegre
-
Porto Alegre, Rio Grande do Sul, 브라질, 90110270
- Centro Gaucho Integrado - Mae de Deus Center
-
-
São Paulo
-
Campinas, São Paulo, 브라질, 13083-878
- Hemocentro Unicamp
-
Jaú, São Paulo, 브라질, 17210120
- Fundação Doutor Amaral Carvalho
-
-
-
-
-
Barcelona, 스페인, 08041
- Hospital de la Santa Creu i Sant Pau
-
Madrid, 스페인, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Seville, 스페인, 41013
- Hospital Universitario Virgen del Rocío
-
Seville, 스페인, 41014
- Hospital Universitario Virgen de Valme
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, 스페인, 28050
- Hospital Universitario HM Sanchinarro
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, 스페인, 33011
- Hospital Universitario Central de Asturias
-
-
-
-
England
-
Birmingham, England, 영국, B9 5SS
- Birmingham Heartlands Hospital
-
-
-
-
-
Salzburg, 오스트리아, 5020
- Uniklinikum Salzburg
-
Vienna, 오스트리아, 1160
- Klinik Ottakring
-
-
-
-
-
Bergamo, 이탈리아, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
-
Brescia, 이탈리아, 25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
-
Meldola, 이탈리아, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milan, 이탈리아, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Milan, 이탈리아, 20162
- ASST Grande Ospedale Metropolitano Niguarda Comitato Etico Milano Area C
-
Monza, 이탈리아, 20900
- Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
-
Novara, 이탈리아, 28100
- Azienda Ospedale Maggiore Della Carita
-
Perugia, 이탈리아, 06132
- Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
-
Ravenna, 이탈리아, 48020
- Ospedale Santa Maria delle Croci
-
Terni, 이탈리아, 05100
- Azienda Ospedaliera Santa Maria Terni
-
Trieste, 이탈리아, 34125
- Azienda sanitaria integrata università di Trieste
-
-
Potenza
-
Rionero in Vulture, Potenza, 이탈리아, 85028
- Irccs Crob
-
-
-
-
-
Aomori, 일본, 030-8553
- Aomori Prefectural Centeral Hospital
-
Fukoka-ken, 일본, 806 8501
- JCHO Kyushu Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 467-8602
- Nagoya City University Hospital
-
-
Chiba
-
Chiba, Chiba, 일본, 260-8717
- Chiba Cancer Center
-
-
Fukui
-
Yoshida-Gun, Fukui, 일본, 910-1193
- Fukui Medical University Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 0030006
- Hokuyukai Sapporo Hokuyu Hospital
-
-
Kochi
-
Nankoku, Kochi, 일본, 783-8505
- Kochi Medical School Hospital
-
-
Miyagi
-
Sendai, Miyagi, 일본, 980-8574
- Tohoku University Hospital
-
Sendai, Miyagi, 일본, 9838520
- NHO Sendai Medical Center
-
-
Saitama
-
Koshigaya, Saitama, 일본, 343 8555
- Dokkyo Medical University - Koshigaya Hospital
-
-
Yamanshi
-
Chūō, Yamanshi, 일본, 409-3821
- University of Yamanashi Hospital
-
-
-
-
-
Beijing, 중국, 100730
- Beijing Hospital
-
Chongqing, 중국, 400030
- Chongqing Cancer Hospital
-
Zhengzhou, 중국, 450008
- Henan Cancer Hospital
-
-
Anhui
-
Hefei, Anhui, 중국, 233004
- Anhui Provincial Cancer Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100191
- Peking University Third Hospital
-
Beijing, Beijing Municipality, 중국, 100034
- Peking University First Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510120
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hubei
-
Wuhan, Hubei, 중국, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, 중국, 410013
- Hunan Cancer Hospital
-
Changsha, Hunan, 중국, 410008
- Xiangya Hospital Central South University
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, 중국, 010050
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330006
- The First Affiliated Hospital of Nanchang University
-
-
Liaoning
-
Shenyany, Liaoning, 중국, 110022
- Shengjing Hospital of China Medical University
-
-
Nanjing
-
Nanjing, Nanjing, 중국, 210029
- Jiangsu Province Hospital
-
-
Shanghai Municipality
-
Changning District, Shanghai Municipality, 중국, 200050
- Shanghai Tongren Hospital
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- West China Hospital of Sichuan University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Tianjin Municipality, 중국, 300020
- Institute of hematology&blood disease hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 311100
- The First People's Hospital of Hangzhou Linping District
-
-
-
-
-
Brno, 체코, 62500
- Fakultni nemocnice Brno
-
Hradec Králové, 체코, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
-
-
-
Braga, 포르투갈, 4710-243
- Centro Clínico Académico - Braga (2CA-Braga) (Hospital de Braga)
-
Lisbon, 포르투갈, 1649035
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Porto, 포르투갈, 4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
-
-
-
-
Biała Podlaska, 폴란드, 21500
- KO-MED Centra Kliniczne
-
Bydgoszcz, 폴란드, 85-168
- Szpital Uniwersytecki nr 1 im. Antoniego Jurasza
-
Katowice, 폴란드, 40519
- Pratia Onkologia Katowice
-
Krakow, 폴란드, 30727
- Pratia MCM Krakow
-
Lublin, 폴란드, 20-090
- Centrum Onkologii Ziemi Lubelskiej
-
Torun, 폴란드, 87-100
- Nasz Lekarz Osrodek Badan Klinicznych
-
Warsaw, 폴란드, 02781
- Narodowy Instytut Onkologii im. Marii Skłodowskiej-Cuire - Państwowy Instytut Badawczy
-
Wroclaw, 폴란드, 50-367
- Uniwersytecki Szpital Kliniczny Klinika
-
-
Legnica
-
Iwaszkiewicza 5, Legnica, 폴란드, 59-220
- Wojewodzki Szpital Specjalistyczny
-
-
Lubelskie V
-
Lublin, Lubelskie V, 폴란드, 20081
- Klinika Hematoonkologii i Transplantacji Szpiku SPSK1 Lublin
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, 폴란드, 80214
- Uniwersyteckie Centrum Kliniczne
-
-
Poznan
-
Skorzewo, Poznan, 폴란드, 60 185
- Centrum Medyczne Pratia Poznan
-
-
-
-
-
Le Mans, 프랑스, 72000
- Hospitalier Le Mans
-
-
-
-
-
Debrecen, 헝가리, 4032
- Debreceni Egyetem Orvos-es Egészsegtudomanyi Centrum
-
Nyíregyháza, 헝가리, 4400
- SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
-
Székesfehérvár, 헝가리, 8000
- Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
-
-
-
-
New South Wales
-
Liverpool, New South Wales, 호주, 2170
- Liverpool Hospital
-
Wentworthville, New South Wales, 호주, 2145
- Westmead Hospital
-
-
Victoria
-
Frankston, Victoria, 호주, 3199
- Peninsula Private Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Confirmed diagnosis of CLL/SLL requiring therapy, per iwCLL 2018 criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Adequate organ function
- Platelets greater than or equal to (≥)75 x 10⁹/liter (L) (≥50 × 10⁹/L for patients with evidence of bone marrow infiltrate), hemoglobin ≥8 grams/deciliter (g/dL), and absolute neutrophil count ≥0.75 x 10⁹/L
- Kidney function: Estimated creatinine clearance ≥40 milliliters per minute (mL/min)
Exclusion Criteria:
-
Known or suspected Richter's transformation at any time preceding enrollment
-
Prior systemic therapy for CLL/SLL
-
Presence of 17p deletion
-
Central nervous system (CNS) involvement
-
Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP])
-
Significant cardiovascular disease
-
Active hepatitis B or hepatitis C
-
Active cytomegalovirus (CMV) infection
-
Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
-
Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count
-
Concurrent use of investigational agent or anticancer therapy except hormonal therapy
-
Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist
-
Vaccination with a live vaccine within 28 days prior to randomization
-
Patients with the following hypersensitivity:
- Known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib or bendamustine
- Prior significant hypersensitivity to rituximab
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm A - Pirtobrutinib
Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity. |
Oral
다른 이름들:
|
|
활성 비교기: Arm B - Bendamustine Plus Rituximab
Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD). |
IV
다른 이름들:
IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)
기간: From randomization until documented disease progression or death (up to 40 months)
|
PFS, as assessed by IRC, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first. |
From randomization until documented disease progression or death (up to 40 months)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator
기간: From randomization until documented disease progression or death (up to 40 months)
|
PFS, as assessed by investigator, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first. |
From randomization until documented disease progression or death (up to 40 months)
|
|
To Evaluate the Effectiveness of Arm A Compared to Arm B: Overall Survival (OS)
기간: Up to approximately 5 years
|
Assessments of effectiveness include OS, assessed by investigator |
Up to approximately 5 years
|
|
Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator
기간: From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)
|
TTNT is defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) including the first dose date of pirtobrutinib for Arm B participants who crossed over to receive pirtobrutinib if applicable or death due to any cause, whichever occurs first. |
From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)
|
|
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC
기간: From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
|
ORR, as assessed by IRC, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm. |
From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
|
|
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator
기간: From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
|
ORR, as assessed by investigator, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm. |
From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
|
|
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by IRC
기간: From first documented response until the first documented disease progression or death (up to 35 months)
|
DoR, as assessed by IRC, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first. |
From first documented response until the first documented disease progression or death (up to 35 months)
|
|
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by Investigator
기간: From first documented response until the first documented disease progression or death (up to 35 months)
|
DoR, as assessed by investigator, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first. |
From first documented response until the first documented disease progression or death (up to 35 months)
|
|
Arm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58
기간: From randomization up to 37 months
|
A measure of CLL/SLL-related symptoms (CLL/SLL-related Symptoms score) was derived from 13 items: appetite loss, fatigue (3 items), pain, nausea, dyspnea, and insomnia from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), and night sweats, fever/chills, and fatigue (3 items) from selected items of the EORTC Item Library set 58 (IL-58). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing worse symptoms. TTW of CLL/SLL-related symptoms was defined as the time from randomization to the earliest date of the first sustained worsening in its score from baseline, meeting or exceeding the meaningful within-person change (MWPC) threshold of +5.12 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints. |
From randomization up to 37 months
|
|
Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30
기간: From randomization up to 37 months
|
Physical Functioning was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Physical Function (PF) scale consisting of 5 items to measure the impact of the disease and its treatment on a participant's ability to perform everyday physical activities, calculated from responses to the five items, each scored on a 4 point scale (1 = not at all to 4 = very much). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing better functioning. TTW of PF was defined as the time from randomization to the earliest date of the first sustained worsening from baseline, with a decline in the meaningful within-person change (MWPC) threshold of -13.33 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints. |
From randomization up to 37 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Arm A Compared to Arm B: Overall Survival, Assessed by Investigator
기간: From randomization until death from any cause (up to 41 months)
|
Overall survival (OS) is defined as the time from randomization until death from any cause. A descriptive analysis of OS was pre-specified based on the primary endpoint data cutoff. |
From randomization until death from any cause (up to 41 months)
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 책임자: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
간행물 및 유용한 링크
일반 간행물
- Eyre TA, Hess LM, Masoudi E, Jen MH, Abhyankar S, Graham-Clarke PL, Bhandari NR, Maguire P, Winfree KB, Tracey M, Taipale KL, Davids MS. Efficacy of Pirtobrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2026 Feb 18;18(4):660. doi: 10.3390/cancers18040660.
- Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2026 Feb 20;44(6):466-475. doi: 10.1200/JCO-25-02380. Epub 2025 Dec 9.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 병리학적 과정
- 신생물
- 만성 질환
- 질병 속성
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 백혈병, B세포
- 림프종
- 백혈병, 림프
- 백혈병
- 병리학적 상태, 징후 및 증상
- 헴 및 림프병
- 림프종, B세포
- 백혈병, 림프구성, 만성, B세포
- 림프종, 비호지킨
- 혈액 질환
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물
- Benzimidazoles
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 산, acyclic
- 카르 복실 산
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 부티레이트
- 항체, 모노클로 날, 뮤린 유래
- 벤다무스틴 염산염
- 리툭시맙
- Pirtobrutinib
기타 연구 ID 번호
기타 연구 ID 번호
- 18088
- LOXO-BTK-20023 (기타 식별자: Eli Lilly and Company)
- J2N-OX-JZNP (기타 식별자: Eli Lilly and Company)
- 2024-511599-33-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .